Regression of Intracranial Meningioma During Treatment with α1-Adrenoceptor Blocker

Overview

Journal J Neurol Surg Rep

Publisher Thieme

Date 2016 May 14

PMID 27175325

Citations 2

Authors

Einar August Hoegestoel

Jon Berg-Johnsen

Affiliations

Soon will be listed here.

Abstract

Background Regression of meningioma has been reported after hemorrhage or hormonal withdrawal. Here, we report a case of an incidentally diagnosed meningioma that regressed in association with α1-adrenoceptor antagonist. Case report A 59-year old male patient with an incidentally diagnosed lateral sphenoid wing meningioma was followed with serial magnetic resonance imaging. The tumor with a maximum diameter of 43 mm showed progressive regression, and after 3 years the size was reduced to 22% of the initial volume. During follow-up the patient was treated with an α1-adrenoceptor antagonist (tamsulosin) for benign prostatic hyperplasia. Possible mechanisms are discussed, including our main hypothesis of reduced mitogenic effects through phospholipase C-signal transduction. Conclusion This is the first report of regression of an incidentally diagnosed meningioma associated with α1-adrenoceptor antagonist treatment.

Citing Articles

Spontaneous regression of a petroclival meningioma: illustrative case.

Noda R, Kawashima M, Akabane A, Inoue T J Neurosurg Case Lessons. 2024; 8(15).

PMID: 39378522 PMC: 11465344. DOI: 10.3171/CASE24416.

Spontaneous regression of a posterior fossa meningioma: A case report.

Takada M, Yanaka K, Nakamura K, Akimoto K, Takeda H, Ishikawa E Surg Neurol Int. 2022; 13:334.

PMID: 36128130 PMC: 9479528. DOI: 10.25259/SNI_429_2022.

References

Masachika E, Kanno T, Nakano T, Gotoh A, Nishizaki T . Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α1-adrenoceptor blocking. Anticancer Res. 2013; 33(3):887-94. View

Hirota K, Fujita T, Akagawa H, Onda H, Kasuya H . Spontaneous regression together with increased calcification of incidental meningioma. Surg Neurol Int. 2014; 5:73. PMC: 4061579. DOI: 10.4103/2152-7806.132957. View

Wen P, Quant E, Drappatz J, Beroukhim R, Norden A . Medical therapies for meningiomas. J Neurooncol. 2010; 99(3):365-78. DOI: 10.1007/s11060-010-0349-8. View

Harris A, Warner B, Wilson J, Becker A, Rowland R, Conner W . Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol. 2007; 178(5):2176-80. PMC: 2084470. DOI: 10.1016/j.juro.2007.06.043. View

Wolfsberger S, Doostkam S, Boecher-Schwarz H, Roessler K, van Trotsenburg M, Hainfellner J . Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev. 2004; 27(4):238-45. DOI: 10.1007/s10143-004-0340-y. View

Touat M, Lombardi G, Farina P, Kalamarides M, Sanson M . Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486). Acta Neurochir (Wien). 2014; 156(10):1831-5. DOI: 10.1007/s00701-014-2188-4. View

de Almeida J, Petteys R, Sciubba D, Gallia G, Brem H . Regression of intracranial meningioma following intratumoral hemorrhage. J Clin Neurosci. 2009; 16(9):1246-9. DOI: 10.1016/j.jocn.2008.11.017. View

Gotoh A, Nagaya H, Kanno T, Nishizaki T . Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells. Pharmacology. 2012; 90(5-6):242-6. DOI: 10.1159/000342797. View

Yoneoka Y, Fujii Y, Tanaka R . Growth of incidental meningiomas. Acta Neurochir (Wien). 2000; 142(5):507-11. DOI: 10.1007/s007010050463. View

10.

Grunberg S, WEISS M, Spitz I, Ahmadi J, Sadun A, Russell C . Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991; 74(6):861-6. DOI: 10.3171/jns.1991.74.6.0861. View

11.

Goncalves A, Page P, Domigo V, Meder J, Oppenheim C . Abrupt regression of a meningioma after discontinuation of cyproterone treatment. AJNR Am J Neuroradiol. 2010; 31(8):1504-5. PMC: 7966109. DOI: 10.3174/ajnr.A1978. View

12.

Vadivelu S, Sharer L, Schulder M . Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. J Neurosurg. 2009; 112(5):920-4. DOI: 10.3171/2009.8.JNS09201. View

13.

Shimizu J, Matsumoto M, Yamazaki E, Yasue M . Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo). 2008; 48(5):227-30. DOI: 10.2176/nmc.48.227. View

14.

Sughrue M, Rutkowski M, Aranda D, Barani I, McDermott M, Parsa A . Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg. 2010; 113(5):1036-42. DOI: 10.3171/2010.3.JNS091966. View

15.

Mikami K, Nagaya H, Gotoh A, Kanno T, Tsuchiya A, Nakano T . Naftopidil is useful for the treatment of malignant pleural mesothelioma. Pharmacology. 2014; 94(3-4):163-9. DOI: 10.1159/000368050. View

16.

Bergoglio M, Gomez-Balaguer M, Almonacid Folch E, Hurtado Murillo F, Hernandez-Mijares A . Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual. Endocrinol Nutr. 2012; 60(5):264-7. DOI: 10.1016/j.endonu.2012.07.004. View

17.

Kyprianou N, Vaughan T, Michel M . Apoptosis induction by doxazosin and other quinazoline alpha1-adrenoceptor antagonists: a new mechanism for cancer treatment?. Naunyn Schmiedebergs Arch Pharmacol. 2009; 380(6):473-7. PMC: 5451152. DOI: 10.1007/s00210-009-0462-4. View

18.

Koide S . Mifepristone. Auxiliary therapeutic use in cancer and related disorders. J Reprod Med. 1998; 43(7):551-60. View

19.

Gruber T, Fabiano A, Deeb G, Lele S, Fenstermaker R . Intracranial meningiomas in patients with uterine sarcoma treated with long-term megestrol acetate therapy. World Neurosurg. 2011; 76(5):477.e16-20. DOI: 10.1016/j.wneu.2011.03.035. View